Xiaorui Yu
Impact in
- Ophthalmology top 5%
- Retinal Diseases and Treatments
- Glaucoma and retinal disorders
-
- Retinal Development and Disorders
- Extracellular vesicles in disease
- Retinoids in leukemia and cellular processes
Papers in
-
- Retinal Diseases and Treatments 3
- Co-authors
- Cheng‐Hu HuMingshu MoYan FengJames F. McGinnisWei CaoBaoying WangSheng LiRaju V. S. Rajala
- Journals
- Journal of Molecular Neuroscience (6 papers)Neuroscience (4 papers)Biomedicine & Pharmacotherapy (2 papers)Cell Death Discovery (1 paper)FEBS Journal (1 paper)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Xiaorui Yu
27 papers receiving 704 citations
Peers
Comparison fields: 5 of 84
- Ophthalmology 110
- Molecular Biology 429
- Neurology 51
- Cancer Research 84
- Endocrine and Autonomic Systems 33
Countries citing papers authored by Xiaorui Yu
This map shows the geographic impact of Xiaorui Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaorui Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaorui Yu more than expected).
Fields of papers citing papers by Xiaorui Yu
This network shows the impact of papers produced by Xiaorui Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaorui Yu. The network helps show where Xiaorui Yu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xiaorui Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 10 | |
| 3 | 2023 | 3 | |
| 4 | 2022 | 2 | |
| 5 | 2022 | 8 | |
| 6 | 2022 | 1 | |
| 7 | 2021 | 15 | |
| 8 | 2021 | 28 | |
| 9 | 2020 | 89 | |
| 10 | 2020 | 4 | |
| 11 | 2018 | 33 | |
| 12 | 2017 | 8 | |
| 13 | 2017 | 12 | |
| 14 | 2016 | 12 | |
| 15 | 2014 | 31 | |
| 16 | 2013 | 18 | |
| 17 | 2013 | 36 | |
| 18 | 2012 | 41 | |
| 19 | 2006 | 36 | |
| 20 | 2004 | 129 |
About Xiaorui Yu
Xiaorui Yu is a scholar working on Ophthalmology, Endocrine and Autonomic Systems, Molecular Biology, Biochemistry and Hematology, having authored 28 papers that have together received 706 indexed citations. Recurring topics across this work include Retinal Development and Disorders (10 papers), Retinoids in leukemia and cellular processes (7 papers), Retinal Diseases and Treatments (3 papers), Erythropoietin and Anemia Treatment (3 papers), Mechanisms of cancer metastasis (3 papers), PARP inhibition in cancer therapy (3 papers), Extracellular vesicles in disease (2 papers) and Neuroscience and Neuropharmacology Research (2 papers). The work is most often cited by research in Ophthalmology (110 citations), Molecular Biology (429 citations), Neurology (51 citations), Cancer Research (84 citations) and Endocrine and Autonomic Systems (33 citations). Xiaorui Yu has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Cheng‐Hu Hu, Mingshu Mo, Yan Feng, James F. McGinnis, Wei Cao, Baoying Wang, Sheng Li, Raju V. S. Rajala, Robert E. Anderson and Feng Li. Their work appears in journals such as Journal of Molecular Neuroscience, Neuroscience, Biomedicine & Pharmacotherapy, Cell Death Discovery and FEBS Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.